

Renal cell metastatic ipilimumab and nivolumab (induction)

ID: 3561 v.8 Endorsed

Treatment must be initiated and supervised by specialist physicians experienced in the treatment of cancer using immunological agents. Before commencing immunotherapy treatment in any patient, clinicians should have an understanding of the immune-related adverse events (irAEs) associated with immunotherapy treatment and their management.

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

The anticancer drug(s) in this protocol <u>may</u> have been included in the ADDIKD guideline. Dose recommendations in kidney dysfunction have yet to be updated to align with the ADDIKD guideline. Recommendations will be updated once the individual protocol has been evaluated by the reference committee. For further information refer to the ADDIKD guideline. To assist with calculations, use the <u>eviQ Estimated Glomerular Filtration Rate (eGFR) calculator</u>.

International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD)

Click here



Related pages:

2022

- Metastatic nivolumab maintenance (weight based dosing) following ipilimumab and nivolumab SUPERSEDED
- Metastatic nivolumab maintenance (flat dosing) following ipilimumab and nivolumab

Treatment schedule - Overview

Cycle 1 to 4

Drug	Dose	Route	Day
Nivolumab	3 mg/kg	IV infusion	1
Ipilimumab	1 mg/kg	IV infusion	1

• If using 4 weekly maintenance dosing, commence maintenance treatment 6 weeks after the last dose of ipilimumab/nivolumab induction.

• If using 2 weekly maintenance dosing, commence maintenance treatment 3 weeks after the last dose of ipilimumab/nivolumab induction.

Frequency: 21 days

4

Cycles:

Notes:

- In clinical trials patients could be treated after progression, provided that they had a clinical benefit and did not have substantial adverse effects, as assessed by the investigator.
- Patients should be assessed for tumour response after 12 weeks i.e. after induction treatment with combination of ipilimumab and nivolumab.
- In the first few months after the start of immunotherapy, some patients can experience transient tumour flare (termed "pseudo progression" or an immune response). This may manifest as growth of existing lesions or the development of new lesions prior to later tumour regression. While this is rare (~5%), continuing treatment and performing a second scan 4 to 6 weeks later to confirm progression may be considered, particularly if the patient remains well.
- Radiation recall has been observed with PD1 inhibitors, consideration should be given to the timing when starting this treatment after a prolonged course of radiation therapy.

Drug status: Ipilimumab and nivolumab are PBS authority

Cost: ~ \$13,870 per cycle

Treatment schedule - Detail

The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are **defaults only** and may be substituted to reflect individual institutional policy. Select here for **recommended doses of alternative antiemetics**.

Cycle 1 to 4

Day 1			
Nivolumab	3 mg/kg (IV infusion)	in 50 mL to 100 mL sodium chloride 0.9% over 30 minutes *	
Ipilimumab	1 mg/kg (IV infusion)	in 50 mL sodium chloride 0.9% over 30 minutes	

• * Wait for 30 minutes after the completion of nivolumab before commencing ipilimumab¹

• If using 4 weekly maintenance dosing, commence maintenance treatment 6 weeks after the last dose of ipilimumab/nivolumab induction.

• If using 2 weekly maintenance dosing, commence maintenance treatment 3 weeks after the last dose of ipilimumab/nivolumab induction.

Frequency: 21 days

4

Cycles:

Treatment schema			
Induction (part 1)	Ipilimumab and nivolumab every 3 weeks (for 4 doses only).		
Maintenance (part 2) - weight based dosing (SUPERSEDED)	Nivolumab every 2 weeks (weight based dosing). Continuous until disease progression or unacceptable toxicity.		
OR			
Maintenance (part 2) - flat dosing	Nivolumab every 2 or 4 weeks (flat dosing). Continuous until disease progression or unacceptable toxicity.		

This protocol is the induction part of the ipilimumab and nivolumab followed by nivolumab regimen.

After 4 cycles of combination therapy with ipilimumab and nivolumab, continue with single agent nivolumab maintenance (weight based or flat dosing).

If using 4 weekly maintenance dosing, commence maintenance treatment 6 weeks after the last dose of ipilimumab/nivolumab induction.

If using 2 weekly maintenance dosing, commence maintenance treatment 3 weeks after the last dose of ipilimumab/nivolumab induction.

Indications and patient population

Indications:

- · First line treatment of advanced unresectable or metastatic intermediate to poor risk clear cell renal cell carcinoma
- ECOG 0-1

Precautions:

If any of these conditions are present, clinical judgement should be used and individual cases discussed with an expert in the field as indicated:

- significant autoimmune disease (e.g. myasthenia gravis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, autoimmune ocular disease)
- organ transplantation
- previous history of viral hepatitis
- HIV/acquired immune deficiency syndrome (AIDS)
- previous radiation to the lungs
- pre-existing deranged liver function tests (this is not predictive of ipilimumab toxicity but extra attention should be applied)
- in patients with asymptomatic or treated brain metastases, clinical judgement should be used and individual cases discussed with an expert in the field
- in patients who have received ipilimumab and stereotactic therapy, case series have reported the development of radiation necrosis at irradiated sites.

Venous access required	IV cannula (IVC) or central venous access device (CVAD) is required to administer this treatment. Read more about central venous access device line selection
Emetogenicity MINIMAL	No antiemetics should be routinely administered before treatment in patients without a history of nausea and vomiting. If patients experience nausea and/or vomiting, consider using the low antiemetic prophylaxis regimen. Read more about preventing anti-cancer therapy induced nausea and vomiting

Immune-related adverse events (irAEs)	Immune-related adverse events (irAEs) can occur early and escalate quickly in patients receiving immune checkpoint inhibitors. IrAEs can also occur after discontinuation of treatment. These events occur at higher frequencies and earlier when nivolumab is administered in combination with ipilimumab when compared to monotherapy. Fatalities have been reported. Management of irAEs is largely based on expert opinion and consensus guidelines. Examples of irAEs with high risk of mortality include: • cardiac toxicity: myocarditis • musculoskeletal toxicity: myositis • neurological toxicity: encephalitis, Guillain-Barré syndrome, myelitis, myasthenia gravis • pulmonary toxicity: encephalitis, Guillain-Barré syndrome, myelitis, myasthenia gravis • pulmonary toxicity: pneumonitis • skin toxicity: Steven-Johnson syndrome, toxic epidermal necrolysis. Examples of irAEs in order of frequency include: • Common • endocrinopathies: thyroid dysfunction • gastrointestinal toxicity: diarrhoea • musculoskeletal toxicity: arthralgia, myalgia • skin toxicity: rash, erythema, pruritus • Less common • endocrinopathies: hypophysitis, type I diabetes mellitus • gastrointestinal toxicity: inflammatory arthritis • ocular toxicity dry eye • renal toxicity • kare • endocrinopathies: primary adrenal insufficiency • gastrointestinal toxicity: pancreatitis • haematological toxicity • musculoskeletal toxicity: pancreatitis • haematological toxicity • cular toxicity: uveitis, iritis. Proactive monitoring, patient self-monitoring and early reporting of adverse events is critical. Treatment interruptions/discontinuation, consultation with specialist and administration of corticosteroids and/or supportive care is required to minimise the risk of death. Read more about the management of immune-related adverse events (irAEs)
Baseline investigations	Consider ECG and troponin at baseline. There is no clear evidence regarding the efficacy/value of baseline ECG or troponin in patients receiving immune checkpoint inhibitor therapy. Some cancer specialists obtain baseline testing, and others continue this through the initial period of therapy. Consider urinalysis at baseline, particularly in patients with additional risk factors for developing immune-related acute kidney injury.
Blood tests	 FBC, EUC, LFTs, serum cortisol, TFTs and BSL at baseline. Repeat FBC, EUC, LFTs and BSL prior to each cycle and serum cortisol and TFTs alternate cycles. N.B for CTLA-4 containing regimens – repeat serum cortisol and TFTs prior to each cycle containing CTLA-4 drug. Check lipase and amylase if symptomatic of pancreatitis. In the absence of suspicion of immune-related adverse events less frequent monitoring may be applicable, according to institutional guidelines. Evidence for the frequency of routine blood testing with immunotherapies varies within published studies and guidelines. Read more about immunotherapy blood test monitoring recommendations.
Hepatitis and HIV	 Hepatitis screening is recommended in all patients who are to receive immune checkpoint inhibitors. Immunotherapy is associated with inflammatory adverse reactions resulting from increased or excessive immune activity and patients are at risk of developing autoimmune hepatitis. It should be used with caution in patients who have a history of chronic hepatic infections (hepatitis B and C), detectable human immunodeficiency virus (HIV) viral load or acquired immune deficiency syndrome (AIDS).

Vaccinations	The safety of having vaccinations during treatment is unknown. Patients in the clinical trials were typically allowed to receive inactivated and recombinant vaccines but not live vaccines. Caution : in patients receiving combination ipilimumab and nivolumab there have been reported cases of fatal myocarditis, myositis and rhabdomyolysis shortly after administration of the influenza vaccine. Whilst a causative relationship to the use of influenza vaccine has not been demonstrated, caution is advised. Read more about COVID-19 vaccines and cancer.
Effects of cancer treatment on fertility	Studies to evaluate the effects of immune checkpoint inhibitor therapy on fertility have not been performed. Therefore, the effect on male and female fertility is unknown. Limited evidence supports that immune checkpoint inhibitor-related hypogonadism due to orchitis and hypophysitis can impact fertility. Immune checkpoint inhibitors can cause fetal harm when given to pregnant women. A pregnancy test should be considered in females of reproductive potential if sexually active. It is important that all patients of reproductive potential use effective contraception whilst on therapy and after treatment finishes. There is very limited evidence to provide guidance regarding contraception timelines. Some studies have demonstrated PD-1 receptor occupancy for greater than 9 months after anti-PD-1 therapy (Brahmer et al., 2010). As a result, some cancer specialists advise using contraception for at least six months or even as long as two years after treatment finishes. Read more about the effect of cancer treatment on fertility

Dose modifications

- · Dose reduction is not recommended
- No dose adjustment is required in the elderly, mild or moderate renal impairment or mild hepatic impairment. Immune checkpoint inhibitors have not been studied in patients with severe renal impairment or moderate to severe hepatic impairment
- When nivolumab is administered in combination with ipilimumab, if either agent is withheld, the other agent should also be withheld. If dosing is resumed after a delay, clinical judgement and/or discussion with an expert in the field is advisable to decide whether the patient should be rechallenged with combination treatment or monotherapy with nivolumab

Management of immune-related adverse events (irAEs)

Link to Management of immune-related adverse events (irAEs)

Interactions

Drug interactions in eviQ protocols are under review and being updated to align with current literature. Further site-wide updates and changes will occur in due course. References & Disclaimer

The drug interactions shown below are not an exhaustive list. For a more comprehensive list and for detailed information on specific drug interactions and clinical management, please refer to the specific drug product information and the following key resources:

- MIMS interactions tab (includes link to a CYP-450 table) (login required)
- Australian Medicines Handbook (AMH) interactions tab (login required)
- Micromedex Drug Interactions (login required)
- Cancer Drug Interactions
- Cytochrome P450 Drug Interactions

	Interaction	Clinical management
Immunosuppressants (inc. corticosteroids)	Reduced efficacy of both immunosuppressants and ipilimumab possible due to pharmacodynamic interaction	It is recommended that patients requiring corticosteroids prior to treatment receive the lowest possible dose (preferably no greater than 10 mg prednisolone or equivalent steroid per day). Once started on ipilimumab the use of corticosteroids to treat immune related adverse events (irAEs) does not appear to impact the clinical response to ipilimumab. In patients requiring ongoing corticosteroids post management of an irAE, the dose should be as low as possible. Monitor for signs of organ rejection in transplant recipients.
Vemurafenib (for melanoma)	Increased risk of hepatotoxicity	Combination not recommended outside of a clinical trial

Nivolumab

No formal pharmacokinetic drug interaction studies have been conducted with nivolumab.

	Interaction	Clinical management
Immunosuppressants (inc. corticosteroids)	Reduced efficacy of both immunosuppressants and nivolumab possible due to pharmacodynamic interaction	It is recommended that patients requiring corticosteroids prior to treatment receive the lowest possible dose (preferably no greater than 10 mg prednisolone or equivalent steroid per day). Once started on nivolumab the use of corticosteroids to treat immune related adverse events (irAEs) does not appear to impact the clinical response to nivolumab. In patients requiring ongoing corticosteroids post management of an irAE, the dose should be as low as possible. Monitor for signs of organ rejection in transplant recipients.

Administration

eviQ provides safe and effective instructions on how to administer cancer treatments. However, eviQ does not provide every treatment delivery option, and is unable to provide a comprehensive list of cancer treatment agents and their required IV line giving set/filter. There may be alternative methods of treatment administration, and alternative supportive treatments that are also appropriate. Please refer to the individual product information monographs via the TGA website for further information.

Day 1

Approximate treatment time: 2 hours

Handling of monoclonal antibodies and waste management

Safe administration

Immunotherapy patient assessment prior to each treatment.

Any toxicity may require delay of treatment and review by medical officer before commencing treatment.

Prime IV line(s).

Insert IV cannula or access TIVAD or CVAD.

Pre treatment medication

Administer antiemetics if required

O Treatment - Time out

Nivolumab

Administer nivolumab:

- a low protein binding 0.2 micron or 1.2 micron inline filter should be used
- via IV infusion over 30 minutes
- observe for infusion-related reactions
- flush with 50 mL of sodium chloride 0.9%.

Mild or moderate infusion-related reaction:

- · decrease the rate of infusion and monitor closely
- give any further doses with close monitoring
- premedication with paracetamol and an antihistamine should be considered for further doses.

Severe infusion-related reaction:

- stop infusion immediately
- medical officer review.

Wait for 30 minutes after the completion of nivolumab before commencing ipilimumab.

Ensure a separate filter is used for ipilimumab.

Ipilimumab

Administer ipilimumab:

- a low protein binding 0.2 micron or 1.2 micron inline filter should be used
- via IV infusion over 30 minutes
- observe for infusion-related reactions
- flush with 50 mL of sodium chloride 0.9%

Mild or moderate infusion-related reaction:

- · decrease the rate of infusion and monitor closely
- give any further doses with close monitoring.
- premedication with paracetamol and an antihistamine should be considered for further doses.

Severe infusion-related reaction:

- stop infusion immediately
- medical officer review.

Remove IV cannula and/or deaccess TIVAD or CVAD.

Discharge information

Patient information

• Ensure patient receives patient information sheet.

The side effects listed below are not a complete list of all possible side effects for this treatment. Side effects are categorised into the approximate onset of presentation and should only be used as a guide.

The most common side effects with this treatment are immune-related adverse events (irAEs). irAEs can escalate quickly and close monitoring of the patient is required. Symptoms should improve promptly after the introduction of immunosuppressive therapy. If this does not occur review the diagnosis and seek further specialist advice. Refer to the Management of immune related adverse events document for further information.

Immune related adverse eve	nts
Cardiotoxicity	 Cardiotoxicity is a rare but serious side effect, which may manifest as asymptomatic reduction in left ventricular ejection fraction (LVEF), arrhythmia, cardiomyopathy, myocarditis, pericarditis, cardiac fibrosis, hypertension, cardiac ischaemia, congestive heart failure (CHF) and cardiac arrest. Read more about Management of immune related adverse events.
Gastrointestinal toxicity	Colitis, diarrhoea or more bowel movements than usual; blood or mucous in stools; dark, tarry, sticky stools; abdominal pain or tenderness. Read more about Management of immune related adverse events
Haematological toxicity	Autoimmune haemolytic anaemia (AIHA), acquired thrombotic thrombocytopenic purpura (TTP), aplastic anaemia (AA), immune thrombocytopenia (ITP), acquired haemophilia (AH), haemolytic uremic syndrome (HUS) and lymphopenia are rare but potentially serious immune- related adverse events associated with immunotherapy treatment. Read more about Management of immune related adverse events.
Hepatotoxicity	Transaminase and total bilirubin elevation, jaundice, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark urine, bleeding or bruising more easily than normal, anorexia. Read more about Management of immune related adverse events.
Musculoskeletal toxicity	Inflammatory arthritis, temporal arteritis, arthralgia, myalgia, synovitis, vasculitis, polymyalgia- like syndrome and myositis. Read more about Management of immune related adverse events.
Neurological toxicity	Aseptic meningitis, myasthenia gravis, Guillain-Barre syndrome, encephalitis, meningeal symptoms, optic neuritis, neuropathy and acute inflammatory demyelinating polyneuropathy are infrequent but potentially serious immune-related adverse events associated with immunotherapy treatment. Read more about Management of immune related adverse events.
Ocular toxicity	Eye pain, blurred vision, Uveitis/iritis, episcleritis, blepharitis, optic neuritis, tear duct stenosis, conjunctivitis, hyperlacrimation, watery or dry eyes and photophobia. Read more about Management of immune related adverse events.
Other endocrinopathies	Type 1 diabetes mellitus, hypophysitis, hypopituitarism and adrenal insufficiency are infrequent but potentially serious immune-related adverse events associated with immunotherapy treatment. Read more about Management of immune related adverse events
Pulmonary toxicity	Radiographic changes, dyspnoea, new or worsening cough, hypoxia, tachycardia, chest pain or fever. Read more about Management of immune related adverse events.
Renal toxicity	Increase in serum creatinine, oliguria, haematuria, peripheral oedema and anorexia. Read more about Management of immune related adverse events.
Skin toxicity	 Rash including full thickness, pruritus, skin blisters, ulceration and necrosis. Radiation recall can occur at site of previous radiation therapy. Symptoms include vesiculation, desquamation and ulceration of the skin. Read more about Management of immune related adverse events
Thyroid toxicity	Thyroid toxicity is common with immune checkpoint inhibitors. Hypothyroidism is most frequent however hyperthyroidism can also occur. Read more about Management of immune related adverse events

Non-immune related adverse events				
Anorexia	Loss of appetite accompanied by decreased food intake.			
	Read more about anorexia			
Fatigue	Read more about fatigue			
Headache				
Nausea and vomiting	Read more about prevention of treatment induced nausea and vomiting			

Evidence

The evidence supporting this protocol is provided by a phase III multicentre international randomised trial (CheckMate 214) involving 1096 patients comparing nivolumab plus ipilimumab with sunitinib alone in patients with previously untreated advanced renal cell carcinoma with a clear-cell component.²

Between October 2014 and February 2016, 550 patients were assigned to the nivolumab plus ipilimumab group, 3 mg/kg and 1 mg/kg respectively given every 3 weeks for 4 doses (induction phase), followed by nivolumab monotherapy 3 mg/kg given every 2 weeks (maintenance phase) until progression or discontinuation due to unacceptable toxicity. Five hundred and thirty five patients were assigned to the sunitinib group and received 50 mg orally once daily for 4 weeks of a 6 week cycle.

The co-primary endpoints were overall survival (OS), objective response rate (ORR) and progression-free survival (PFS) among patients with intermediate- or poor-risk by IMDC prognostic score criteria. Exploratory endpoints included the OS, ORR and PFS among favourable-risk patients.

Efficacy

The results of the interim and subsequent analyses amongst intermediate or poor-risk patients are summarised in the table below. The combination of ipilimumab and nivolumab was shown to be superior to sunitinib for all three co-primary endpoints. Importantly, more responses to nivolumab plus ipilimumab were complete (10.4%) and durable (65.2% ongoing response) compared with sunitinib (1.4% complete response, 49.6% ongoing response).³


An exploratory analysis of favourable-risk patients in the interim analysis uncovered improved outcomes in the sunitinib group compared to the nivolumab plus ipilimumab group, with higher ORR of 52% (95% CI 9.7-20.3) vs 29% (95% CI 21-38) (p<0.0001), and prolonged median PFS (25.1 months vs 15.3 months, HR=2.2; 99% CI 1.3 to 3.7; p<0.0001).² The differences in PFS were not statistically significant at second interim analysis (HR=1.2; 95% CI 0.9 to 1.7; p=0.19).⁴Subsequent analysis confirmed favourable PFS outcomes in the sunitinib arm (HR=1.84; 95% CI 1.29 to 2.62), yet the differences in PFS between arms decreased over time. ORR remained higher in the sunitinib arm (51.6%; 95% CI 43 to 61; p<0.0005) compared to the nivolumab plus ipilimumab arm (29.6%, 95% CI 22 to 38). However, more responses in the nivolumab plus ipilimumab group were complete (12% vs 6.5%) and durable (64.9% vs 56.3%).³ Ongoing follow-up and data maturation for this patient subgroup is required before definitive conclusions can be made regarding optimal therapy.

Summary of co-primary endpoint analysis at each interim analysis for intermediate and poor-risk patients


Primary endpoint	First interim analysis (median 25.2 mo follow-up) ²		Second interim analysis (median 32.4 mo follow-up) ⁴		Third interim analysis (median 55 mo follow-up) ³	
	Ipilimumab/nivolumab	Sunitinib	lpilimumab/nivolumab	Sunitinib	lpilimumab/nivolumab	Sunitinib
	NR	26.0	NR	26.6	48.1	26.6
	HR 0.63 99.8% CI 0.44-0.89; p<0.001		HR 0.66 95% CI 0.54-0.80; p<0.0001		HR 0.65 95% CI 0.54-0.78	
Overall response rate (%, 95% Cl)	42 (37-47)	27 (22- 31)	42 (37-47)	29 (25- 34)	41.9 (37.1-46.7)	26.8 (22.6- 31.3)
Progression-free	11.6	8.4	8.2	8.3	11.2	8.3
survival (median, mo)	HR 0.85 99.1% CI 0.64-1.05;	p=0.03	HR 0.77 95% Cl 0.65-0.90; p=	0.0014	HR 0.74 95% CI 0.62-0.8	38

mo= months; NR= not reached

Kaplan-Meier curve for overall survival in IMDC intermediate-risk or poor-risk patients³



Kaplan-Meier curve for progression-free survival per investigator assessment in IMDC intermediate-risk or poor-risk patients³




Toxicity

Treatment-related adverse events were reported in 94% of those receiving nivolumab plus ipilimumab and 97% in those receiving sunitinib.⁴ The most common severe toxicities (grade 3 or 4) experienced in both regimens are summarised below. Severe toxicity for nivolumab plus ipilimumab tended to occur within or soon after the initial four cycle induction phase, with far fewer events during the maintenance nivolumab phase. In comparison, patients who received sunitinib experience chronic toxicity in a cumulative fashion, especially vascular-related adverse events.

Treatment discontinuation due to adverse events occurred in 22% of patients in the nivolumab plus ipilimumab group vs 12% in the sunitinib group. The use of corticosteroids (\geq 40 mg prednisolone daily or equivalent) to manage treatment-related select adverse events occurring within 30 days of last dose in the nivolumab plus ipilimumab group was 29% (157/547). There were eight (1%) treatment-related deaths in the nivolumab plus ipilimumab group and four (<1%) treatment-related deaths in the sunitinib group.²

Adverse events⁴



References

- 1 Bristol-Myers Squibb Pharmaceuticals. Ipilimumab product information. 2019.
- 2 Motzer, R. J., N. M. Tannir, D. F. McDermott, et al. 2018. "Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma." N Engl J Med 378(14):1277-1290.
- 3 Albiges, L., N. M. Tannir, M. Burotto, et al. 2020. "Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial." ESMO Open 5(6).
- 4 Motzer, R. J., B. I. Rini, D. F. McDermott, et al. 2019. "Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial." Lancet Oncol 20(10):1370-1385.

History

Version 8

Date	Summary of changes	
13/04/2022	Protocol updated based on the consensus gained at the immunotherapy reference committee meeting held on 4 th of March 2022. The following changes have been made across all immune checkpoint inhibitor protocols:	
	 Indications and patient populations- previous radiation to the lungs added to precautions. Clinical information- general irAEs, hepatitis and HIV, and fertility blocks updated. Individual irAE-related blocks removed. New block (baseline investigations) added. 	
	 Patient information- pregnancy and breastfeeding block in general advice section updated. Version number increased to V.8. 	
30/09/2022	Protocol reviewed electronically by Medical Oncology Reference Committee. No changes. Next review in 4 years.	

Version 7

	Date	Summary of changes
--	------	--------------------

11/05/2021	Blood tests in clinical information section updated to align with other immune checkpoint inhibitor protocols. Version increased to V.7.
09/11/2021 Patient information title changed to "Kidney cancer advanced or metastatic".	

Version 6

Date	Summary of changes
09/02/2021	Efficacy section updated to include CheckMate 214 trial third interim results. Version increased to V.6.

Version 5

Date	Summary of changes	
12/11/2020	Protocol updated to align with ID 1993 Management of immune-related adverse events (irAEs) clinical resource which has been electronically reviewed and approved by the eviQ immunotherapy reference committee. The following changes have been made across all immune checkpoint inhibitor protocols:	
	 Treatment schedule - additional note added: radiation recall. Clinical information- cardiotoxicity, haematological toxicity, musculoskeletal toxicity and ocular toxicity added; rheumatological toxicity removed; immunotherapy clinical information changed to alphabetical order. Side effects- haematological added; rheumatological replaced with musculoskeletal; immunotherapy side effects changed to alphabetical order. Arthralgia and myalgia non-irAE side effect removed to align with other immune checkpoint inhibitor protocols. Version number increased to V.5. 	

Version 4

Date	Summary of changes
14/09/2020	Protocol reviewed electronically by Medical Oncology Reference Committee. Efficacy and toxicity data updated. Version number changed to V.4.

Version 3

Date	Summary of changes	
20/01/2020	Treatment schedule, treatment schema, patient information and related pages updated to nivolumab maintenance weight based and flat dosing options (ID 3682 and ID 3677). Premedication block removed from clinical information. Indications and side effects updated. Version number changed to V.3.	

Version 2

Date	Summary of changes	
15/03/2019	ew protocol taken to Medical Oncology Reference Committee meeting.	
02/04/2019	Protocol approved and published on eviQ. Review in 1 year.	
29/04/2019	Ipilimumab diluent volume changed from 100 mL to 50 mL. Version increase to V.2	
31/05/2019	1/05/2019 Drug status updated to PBS authority.	

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ's disclaimer available at www.eviQ.org.au

First approved:28 March 2019Last reviewed:30 September 2022Review due:31 December 2026

The currency of this information is guaranteed only up until the date of printing, for any updates please check: https://www.eviq.org.au/p/3561 16 Jun 2023



Patient information - Kidney cancer advanced or metastatic - Ipilimumab and nivolumab

Patient's name:

Your treatment

It is important to understand that nivolumab and ipilimumab are not traditional chemotherapy drugs and have a different way of working. They are immunotherapy treatments (also called anticancer drugs) that work with your immune system to detect and destroy cancer cells. Immunotherapy can potentially affect any organ of the body.

The treatment schedule below explains how the immunotherapy drugs for this treatment are given.

Ipilimumab and nivolumab

This treatment cycle (ipilimumab and nivolumab) is repeated every 21 days. You will have 4 cycles. This is then followed by single agent nivolumab every 14 or 28 days. Your doctor will advise you of how often you will have your treatment and the number of treatments you will have.

Day	Treatment	How it is given	How long it takes
1	Nivolumab (nee-vol-u-mab)	By a drip into a vein	About 2 hours
	lpilimumab (ipi-lim-u-mab)		

Prior to your treatment tell your doctor if you are taking any other medicines (e.g. corticosteroids, immunosuppressive therapy), have or ever had chronic liver infections e.g. hepatitis B (HBV) or C (HCV), human immunodeficiency virus (HIV) or an organ transplant.

When to get help

Emergency contact details

Ask your doctor or nurse from your treating team who to contact if you have a problem

1		
	_	

It is important that you tell your doctor or nurse immediately if you develop any of the symptoms listed below in the side effects section. If you can't contact your doctor or nurse, go to your nearest hospital Emergency Department for help.

During your treatment immediately tell the doctor or nurse looking after you if you get any of the following problems:

- leaking from the area where the drugs are being given
- pain, stinging, swelling or redness in the area where the drugs are being given
- a skin rash, itching, feeling short of breath, wheezing, fever, shivers, or feeling dizzy or unwell in any way (allergic reaction).

Other information about your treatment

Treatment delays

There may be times when your treatment is delayed. This can happen if your doctor thinks you are likely to have severe side effects, if you get severe side effects, if your blood counts are affected and causing delays in treatment, or if you are finding it hard to cope with the treatment. Your doctor will explain if you need any delays to your treatment and the reason why.

Blood tests and monitoring

You will need to have a blood test before you start treatment and regularly throughout your treatment. Your doctor or nurse will tell you when to have these blood tests.

Other medications given during this treatment

• Steroids: you may be given some steroid tablets to help reduce immune-related side effects. Your doctor or nurse will tell you how and when to take the steroids. You may need to monitor your blood sugar levels closely while you are taking steroids. If you have diabetes, your diabetic medication may need to be adjusted because of the effects of steroids. Speak to your diabetes advisor.

Side effects

Cancer treatments can cause damage to normal cells in your body, which can cause side effects. Everyone gets different side effects, and some people will have more problems than others.

The table below shows some of the side effects you may get with this treatment. You are unlikely to get all of those listed and you may also get some side effects that have not been listed.

Tell your doctor or nurse about any side effects that worry you. Follow the instructions below and those given to you by your doctor or nurse.

Immunotherapy may cause serious immune reactions against your own body. These are called immune-related adverse events. They may occur during your treatment, or after your treatment has ended. Immunotherapy can affect many parts of your body. Some side effects can cause severe or life threatening conditions, so even mild side effects must be reported immediately. Do not try to treat these symptoms yourself without talking to your doctor or nurse first. You will be given an information pack at the start of your treatment. This contains an alert card which you should carry with you at all times. Bring this alert card with you to hospital, especially if you are unwell or attending the emergency department.

Immune related side effects	
Heart problems	 You may get: chest pain or tightness shortness of breath swelling of your ankles an abnormal heartbeat. Heart problems are uncommon but potentially fatal. If heart problems were to occur, symptoms usually start within the first 3 months of treatment, but can happen at any time even after the treatment has finished. Tell your doctor if you have a history of heart problems or high blood pressure. Before or during treatment, you may be asked to have a test to see how well your heart is working. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you get any of the symptoms listed above.

Bowel and stomach inflammation	 You may get: bowel motions (stools, poo) that are more frequent or more liquid (diarrhoea) blood or mucous in your stool dark, tarry, or sticky bowel motions bloating, cramping, pain or tenderness in your stomach area. Inform your doctor or nurse immediately if you get diarrhoea Take your anti-diarrhoeal or steroid medication as directed by your doctor. Drink plenty of fluids (unless you are on a fluid restriction). Eat and drink small amounts more often. Avoid spicy foods, dairy products, high fibre foods, and coffee. Tell your doctor or nurse immediately, or go to your nearest hospital Emergency Department if your diarrhoea is not controlled despite taking anti-diarrhoea medicine, severe stomach pains and bloating, and/or if you feel dizzy or light-headed.
Blood problems	 Blood problems are infrequent but can be serious. You may feel dizzy, light-headed, tired, weak and appear more pale than usual. You may get: dark, tarry bowel motions (stools, poo) blood in your urine or not urinating as often dark-coloured urine yellowing of the whites of your eyes, and/or your skin pinpoint red spots on your skin unexplained bleeding major bruising a fever shortness of breath a severe headache confusion faster heartbeat than normal Tell your doctor or nurse immediately or go to the nearest hospital Emergency Department if it has been longer than 12 hours since you have emptied your bladder or if you get any of the symptoms listed above.
Liver damage	 You may get: fatigue severe nausea and vomiting weight loss bruising or bleeding more easily pain or tenderness on the right side of your stomach area dark coloured urine yellowing of the whites of your eyes and/or your skin itchy skin drowsiness You will have regular blood tests to check how well your liver is working. Take your steroid medication as directed by your doctor. Tell your doctor or nurse as soon as possible if you notice that your urine is a dark colour, the whites of your eyes or skin look yellow, if you have unexplained bruising or bleeding or if you have severe stomach pain.
Muscle and joint problems	 You may get: muscle or joint stiffness, especially after a period of rest muscle weakness pain in your muscles or joints joint swelling tiredness headaches Take your pain relief or steroid medication as directed by your doctor. Tell your doctor or nurse as soon as possible if you get any of the symptoms listed above.

	Nervous system changes are rare, but can be serious.
Nervous system problems	 You may get: headaches fever stiff neck confusion or difficulty concentrating dizziness or drowsiness loss of consciousness muscle weakness or pain numbness or tingling in your hands or feet jerky movements. Take your steroid medication as directed by your doctor. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you get any of the symptoms listed above.
Eye problems	 You may get: eye pain itchy eyes red or swollen eyes blurred or change in vision change in colour vision watery or gritty eyes dry eyes sensitivity to light. Protect your eyes from the weather (sun and wind) by wearing sunglasses. Use your eye drops or take your steroid medication as directed by your doctor. Tell your doctor or nurse as soon as possible if you get any of the symptoms listed above.
Hormone problems	 Hormone changes are infrequent, but can be serious. You may get: headaches tiredness, dizziness or fainting abnormal heartbeat (faster than usual) a feeling of being hot or cold more easily excessive sweating weight changes a deepened voice irregular or absent periods nausea and vomiting thirsty and need to urinate more often than normal high blood sugar levels pain in your stomach area muscle pain or weakness difficulty sleeping agitated more easily changes in your mood or behaviour, such as decreased sex drive or irritability. Take your hormone or steroid medication as directed by your doctor. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you feel confused, weak, dizzy, or faint, or get sudden pain in your lower back or legs.

Lung problems	 You may get: shortness of breath difficulty breathing faster heartbeat than normal chest pain new or worsening cough fever. Your doctor will monitor how well your lungs are working during your treatment. Take your steroid medication as directed by your doctor. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you have chest pain or become short of breath.
Kidney damage	 This treatment can cause changes to how your kidneys work. You may get: a feeling of needing to urinate less often than normal blood in your urine swollen hands and feet loss of appetite. You will have regular blood tests to check how well your kidneys are working. You may need to drink more fluids while you are having treatment. Your doctor or nurse will tell you if you need to do this. Take your steroid medication as directed by your doctor. Tell your doctor or nurse as soon as possible if you notice that your urine changes colour or you don't need to empty your bladder as often.
Skin rash	 You may get a red rash a bumpy rash dry and itchy skin skin peeling or blisters. if you have had previous radiation therapy to an area this effect may be worse Moisturise your skin with a gentle non-perfumed moisturising cream like sorbolene or aqueous cream. Avoid scratching your skin. Avoid wearing tight fitting clothing Protect your skin from the sun by wearing sun-protective clothing, a wide-brimmed hat, sunglasses and sunscreen of SPF 50 or higher. Take your antihistamine medication or apply your steroid cream as directed by your doctor. Tell your doctor or nurse as soon as possible if you notice any changes to the rash like pain or pus forming.

Thyroid problems

Thyroid problems are common with this treatment. The most common problem is an underactive thyroid gland (hypothyroidism), occasionally you may get an overactive thyroid gland (hyperthyroidism).

- If you have an **underactive** thyroid, you may get:
 - $\circ~$ fatigue and low energy levels
 - depression
 - slow heart rate
 - unexplained weight gain
 - intolerance to cold temperatures
 - fatigued and aching muscles
 - dry, coarse skin
 - puffy face
 - hair loss
 - constipation
 - problems with concentration
 - changes in your periods
- If you have an **overactive** thyroid, you may get
 - abnormal heartbeat (faster than usual)
 - a feeling of being hot or cold more easily
 - excessive sweating
 - difficulty sleeping
 - anxiety, nervousness or agitated more easily
 - diarrhoea
 - changes in your periods
- You will have regular blood tests to check how well your thyroid is working.
- Take your hormone or steroid medication as directed by your doctor.
- Tell your doctor or nurse if you get any of the symptoms listed above.

Non-immune related side effe	cts
Appetite loss (anorexia)	 You may not feel like eating. Try to avoid drinking fluids at meal times. Try to eat small meals or snacks regularly throughout the day. Try to eat food that is high in protein and calories. If you are worried about how much food you can eat, or if you are losing weight, ask to speak to a dietitian.
Tiredness and lack of energy (fatigue)	 You may feel very tired, have no energy, sleep a lot, and not be able to do normal activities or things you enjoy. Do not drive or operate machinery if you are feeling tired. Nap for short periods (only 1 hour at a time) Prioritise your tasks to ensure the best use of your energy. Eat a well balanced diet and drink plenty of fluids (unless you are fluid restricted). Try some gentle exercise daily. Allow your friends and family to help. Tell your doctor or nurse if you get any of the symptoms listed above.
Headache	 You can take paracetamol if you have a headache. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you get a very bad headache that is not helped by pain medication.
Nausea and vomiting	 You may feel sick (nausea) or be sick (vomit). Drink plenty of fluids (unless you are fluid restricted). Eat small meals more frequently. Try food that does not require much preparation. Try bland foods like dry biscuits or toast. Gentle exercise may help with nausea. Anti-sickness medication is usually not needed but may help in some people. Ask your doctor or nurse for eviQ patient information - Nausea and vomiting during cancer treatment. Tell your doctor or nurse immediately, or go to the nearest hospital Emergency Department if you have uncontrolled vomiting or feel dizzy or light-headed.

General advice for people having cancer treatment

Blood clot risk

- Cancer and anticancer drugs can increase the risk of a blood clot (thrombosis).
- Tell your doctor if you have a family history of blood clots.
- A blood clot can cause pain, redness, swelling in your arms or legs, shortness of breath or chest pain.
- If you have any of these symptoms go to your nearest hospital Emergency Department.

Medications and vaccinations

- Before you start treatment, tell your doctor about any medications you are taking, including vitamins or herbal treatments.
- Don't stop or start any medications during treatment without talking to your doctor and pharmacist first.
- Paracetamol is safe to take if you have a headache or other mild aches and pains. It is recommended that you avoid taking aspirin, ibuprofen and other anti-inflammatory type medications for pain while you are having treatment. However, if these medications have been prescribed by your doctor, do not stop taking them without speaking with your doctor.
- Don't have any vaccinations without talking to the doctor who is managing your cancer treatment.
- People you live with should be fully vaccinated, according to the current vaccination schedule. Extra care needs to be taken with hand washing and careful disposal of soiled nappies for infants who have recently received the rotavirus vaccine.

Other medical and dental treatment

- If you go to hospital or any other medical appointment (including dental appointments), always tell the person treating you that you are receiving anticancer drugs.
- Before you have any dental treatment, talk to your doctor.

Diet

- While you are receiving this treatment it is important that you try to maintain a healthy diet.
- Speak to your doctor or nurse about whether drinking alcohol is safe with your treatment.
- If you have any concerns about recent weight loss or weight gain or questions about your diet, ask to speak to a dietitian.

Fertility

- Some cancer treatments can reduce your fertility. This can make it difficult or impossible to get pregnant or father a child.
- Talk to your doctor or nurse before you start any treatment. Depending on your situation there may be fertility sparing options available to you and/or your partner, discuss these with your doctor or nurse.

Pregnancy and breastfeeding

- Some cancer treatments can be dangerous to unborn babies. Talk to your doctor or nurse if you think there is any chance that you could be pregnant.
- Do not try to get pregnant or father a child during this treatment. Contraception should be used during treatment and after stopping treatment. Ask your doctor or nurse about what type of contraception you should use.
- If you are planning pregnancy/fatherhood after completing this treatment, talk to your doctor. Some doctors advise waiting between 6 months and 2 years after treatment.
- Do not breastfeed if you are on this treatment, as anti-cancer medications can also pass into breast milk.

Sex life and sexuality

- The desire to have sex may decrease as a result of this treatment or its side effects.
- Your emotions and the way you feel about yourself may also be affected by this treatment.
- It may help to discuss your concerns with your partner and doctor or nurse.

Quitting smoking

- It is never too late to quit smoking. Quitting smoking is one of the best things you can do to help your treatment work better.
- There are many effective tools to improve your chances of quitting.
- Talk to your treating team for more information and referral to a smoking cessation support service.

Staying active

- Research shows that exercise, no matter how small, has many benefits for people during and after cancer treatment.
- Talk to your doctor before starting an exercise program. Your doctor can advise whether you need a modified exercise program.

For more information about cancer treatment, side effects and side effect management see our Patient and carers section.

Where to get more information

Telephone support

• Call Cancer Council on 13 11 20 for cancer information and support

Kidney cancer information

- Kidney Cancer Association kidneycancer.org/
- Kidney Health Australia kidney.org.au

General cancer information and support

- Australian Rare Cancer (ARC) Portal arcportal.org.au/
- Beyondblue beyondblue.org.au
- Cancer Australia canceraustralia.gov.au
- Cancer Council Australia cancer.org.au
- Cancer Voices Australia cancervoicesaustralia.org
- CanTeen canteen.org.au
- Carers Australia carersaustralia.com.au
- CHILL Cancer related hair loss scalpcooling.org
- eviQ Cancer Treatments Online eviQ.org.au

- LGBTQI+ People and Cancer cancercouncil.com.au/cancer-information/lgbtqi
- Look Good Feel Better lgfb.org.au
- Patient Information patients.cancer.nsw.gov.au
- Radiation Oncology Targeting Cancer targetingcancer.com.au
- Redkite redkite.org.au
- Return Unwanted Medicines returnmed.com.au
- Staying active during cancer treatment patients.cancer.nsw.gov.au/coping-with-cancer/physical-wellbeing/staying-active

Quit smoking information and support

Quitting smoking is helpful even after you have been diagnosed with cancer. The following resources provide useful information and support to help you quit smoking. Talk to your treating team about any other questions you may have.

- Call Quitline on 13 QUIT (13 78 48)
- iCanQuit iCanQuit.com.au
- Patient Information patients.cancer.nsw.gov.au/coping-with-cancer/physical-wellbeing/quitting-smoking
- Quitnow quitnow.gov.au

Additional notes:

This document is a guide only and cannot cover every possible situation. The health professionals caring for you should always consider your individual situation when making decisions about your care. Contact your cancer clinic staff or doctor if you have any questions or concerns about your treatment, or you are having problems coping with side effects. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use of this document is subject to eviQ's disclaimer available at www.eviQ.org.au

First approved:28 March 2019Last reviewed:30 September 2022Review due:31 December 2026

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/pi/3561 16 Jun 2023